- Approximately 8.95 Million Shares Shorted Since November 2011
- Short Squeeze Has Begun As Stock Above $2.34 SqueezeTrigger
NEWPORT BEACH, Calif., Jan. 3, 2013 (GLOBE NEWSWIRE) -- BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has updated coverage on TherapeuticsMD TXMD after releasing the latest short sale data through December 26, 2012. The total aggregate number of shares shorted since November 2011 is approximately 8.95 million shares. Approximately 25.3% of daily trading volume is short selling. The SqueezeTrigger price for all TXMD shares shorted is $2.34. A short squeeze has begun as TXMD is above the $2.34 SqueezeTrigger Price.
Click for original Report: http://www.buyins.com/reports/txmd11-19-12.pdf
Click for updated SqueezeTrigger: http://www.buyins.com/images2/txmdstr12-27-12.jpg
Click for updated Friction Factor: http://www.buyins.com/images2/txmdff12-27-12.jpg
Click for detailed explanation: http://www.buyins.com/brochure.pdf
Friction Factor calculates if a fair market is being made in the shares of TXMD. 43% of the previous 37 trading days have been positive or bullish-biased and 57% have been negative or bearish-biased.
Regulation SHO requires bona-fide market-making activities to include making purchases and sales in roughly comparable amounts. The Commission has stated that bona-fide market-making DOES NOT include activity that is related to speculative selling strategies or investment purposes of the broker-dealer and is disproportionate to the usual market making patterns or practices of the broker-dealer in that security. Likewise, where a market-maker posts continually at or near the best offer, but does not also post at or near the best bid, the market-maker's activities would not generally qualify as bona-fide market-making. Moreover, a market-maker that continually executes short sales away from its posted quotes would generally not be considered to be engaging in bona-fide market-making.
BUYINS.NET monitors TXMD market-makers daily for compliance with Fair Market-Making Requirements.
BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies and comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.
INVESTMENTS & TRADING
SqueezeTrigger -- 36 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.
GATS -- tracks and quantifies known trading strategies.
BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. A third party has paid $1,116 per month to purchase data to be provided in twelve monthly reports. TXMD has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.